GALILEO PRODUCTS BY SECTOR

Darren Diamond brings over 30 years of experience in general management, corporate finance, strategic planning, budget planning and performance analysis to the Galileo Biologics team. 

Diamond possesses considerable entrepreneurial experience having founded his own consulting and corporate finance advisory firm in 1996. Diamond gained the bulk of his business analysis, financial structuring and corporate finance advisory experience during assignments at Citicorp Securities and FleetBoston Securities where he worked primarily with highly leveraged and/or restructuring companies. 

Diamond has broad experience in a variety of industry sectors, including Retailing, Manufacturing, Consumer Goods (manufacturing & distribution), Medical Services, Advertising/Media, Energy & Environmental Management, Infrastructure and Public Works, and Real Estate. 

Diamond holds a Master of Business Administration (Finance) from the Wharton School at the University of Pennsylvania and a Bachelor of Arts (Economics) from Yale University.

Christopher Galliano brings over 20 years of experience in innovation, invention, and  technology development, complemented by significant expertise in leveraging the power of Human Collaboration Learning (CL) in AI-based  drug discovery. He has collaborated with researchers from the University of British Columbia (UBC) and Louisiana State University (LSU), making valuable contributions to publications in this field. 

Mr. Galliano has co-authored 6 patents in AI-based drug discovery and has played a key role in the development of the world's first AI-derived LONG COVID therapeutic approved for late-stage clinical trials.

Galliano is among the pioneers in patenting the use of Nutraceuticals in the treatment of Coronavirus diseases. He was a guest lecturer and presenter on this topic at Supply Side West in Las Vegas in 2022.

 Previously serving as the Executive Officer of Space and Naval Warfare Systems Center New Orleans, Galliano played a pivotal role in advancing  the Navy's initial cloud-based computing technologies, which supported  over 40 concurrent programs during his tenure. 

  He was awarded the Navy's Humanitarian Medal for his leadership during Operation Unified Assistance, one of the largest humanitarian crises in  history, in the wake of the Great Tsunami. Galliano's service during  this period involved relief mission planning as the Amphibious Operations Officer in Sri Lanka and Indonesia. 

Ronnie Rodriguez, CPA brings 30 years of financial management and accounting experience to the Galileo Biologics team. 

He is the former Director of Accounting for LSU Medical School, and has been a Vice President of Finance and Business affairs at Nicholls State University and served as a Vice Chancellor at Delgado Community college and Nunez Community College where he oversaw the budgeting and accounting across 3 university systems in Louisiana. 

Mr Rodriguez is a certified State Auditor in the State of Louisiana. 

Mr. Rodriguez is a Certified Public Accountant (CPA) and holds the following additional certifications. 

· Securities Industry Essentials Exam, February 2021

· Series 7 Top Off Exam, March 2021

· Series 66 Uniform Combined State Law Exam, March 2021

· LA Life, Health and Accident or Sickness Insurance Series 103 Exam, April 2021 Certified Information Systems Auditor, July 2000

· Licensed Certified Public Accountant, August 1998.

Galileo Biologics is scientifically led by Dr. V, one of the most respected scientists in lipid based delivery systems and was an early pioneer in the fields of thermal resistance and gas based responses factoring in lipid designs. 

Dr. V has led the development of over 60 trade secrets over the last 35 years.

Dr. V leads the day to day research and development of micelle technologies. 

The Galileo Biologics team has dedicated over 20 years to the multi-faceted feature and capability set of the micelle technology. Dr. V has authored and maintains trade secrets on over 100 formulations and maintains the Galileo library of over sixty off the shelf, custom micelle payload/capabilities. 

Igor Rusietsky brings over 15 years of experience in marketing, branding, product development, manufacturing, engineering, and project management to Galileo Biologics. 

Mr. Rusietsky is highly regarded as a Program Manager in multiple verticals including the pharmaceutical and clinical trial development sectors, where he has collaborated with Clinical Research Organizations, Manufacturers, and global supply chain distribution and logistics planning entities.

The development of oral insulin and humanitarian assistance initiatives require significant investment, with hundreds of millions of dollars directed toward these processes annually. Galileo Biologics has already accumulated preliminary data from per-clinical trials of the oral insulin prototype and is prepared for its commercial launch. 

Igor is passionate about invention & science and is working across our cross-functional team to advance oral insulin in various forms, including tablets, sprays, and chewable gummy gel, potentially eliminating the need for subcutaneous injections globally and positively impacting the lives of millions of children and adults.

Mr. Rusietsky holds a degree in Electrical Engineering and a Masters from the Kyiv School of Economics.

Volodymyr Ostapenko brings 30 years of development experience to the Galileo Biologics team. 

He has been a part over the development of over 25 products that have achieved commercialization over the last 3 decades. 

He is the operational and research and development leader of our research lab in the Netherlands where he and Dr. V spend their time conducting research and enjoying the beautiful nature of the Netherlands. 

Under his leadership, the Galileo Biologics team has invested over $8.5 million over the last 20 years to further advance the capabilities of of the lipid micelle technologies.